# FCGR2B Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *FCGR2B* gene encodes FcγRIIb, a low-affinity inhibitory IgG receptor crucial for negative regulation of B-cell receptor signaling, antibody production, and phagocytosis, with its expression on B cells, myeloid cells, and dendritic cells positioning it centrally in humoral immunity and autoimmunity.
- Genetic variations, particularly promoter polymorphisms (−386 G/C, −120 A/T, −343 G/C) and the transmembrane variant Ile232Thr (rs1050501), are robustly associated with increased susceptibility to autoimmune diseases like Systemic Lupus Erythematosus (SLE) and immune thrombocytopenia (ITP) by reducing FcγRIIb surface expression and impairing inhibitory signaling.
- In the tumor microenvironment, FcγRIIb expression on tumor-associated macrophages (TAMs) impedes antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC), representing a significant mechanism of immune evasion and resistance to therapeutic monoclonal antibodies, leading to investigational therapies like BI-1206 that target FcγRIIb blockade.
- FcγRIIb's inhibitory signaling cascade, initiated by ITIM phosphorylation and recruitment of SHIP1, is critical for maintaining B-cell tolerance and dampening myeloid cell activation, with its dysregulation contributing to autoantibody production and inflammatory responses.
- Structural analysis reveals FcγRIIb's Ig-like extracellular domains bind IgG Fc with low affinity, while its cytoplasmic tail contains a key ITIM motif essential for recruiting SHIP1 and initiating inhibitory signaling, with N-glycosylation and palmitoylation influencing its function and localization.
- *FCGR2B* gene locus is characterized by extensive segmental duplications and non-allelic homologous recombination, contributing to inter-individual genetic diversity, and chromosomal translocations involving *FCGR2B* have been identified in malignant lymphomas, such as follicular lymphoma, disrupting normal gene regulation.

---

## Executive Summary & Key Metadata

The **FCGR2B** gene encodes the Fc gamma receptor IIb (FcγRIIb, CD32B), a low-affinity inhibitory receptor for the Fc region of immunoglobulin G (IgG). As the sole inhibitory receptor among the classical Fcγ receptor family, FcγRIIb functions as a critical negative regulator of immune cell activation, B-cell receptor (BCR) signaling, antibody production, and phagocytosis. Its expression on B lymphocytes, plasmablasts, monocytes, macrophages, dendritic cells, and certain endothelial cells positions it at the nexus of humoral immunity, autoimmunity, and tumor immunology. Genetic variation in *FCGR2B*, including promoter polymorphisms, non-synonymous coding variants, and copy number alterations, has been robustly associated with susceptibility to systemic lupus erythematosus (SLE), anti-glomerular basement membrane (anti-GBM) disease, IgA nephropathy, immune thrombocytopenia (ITP), and various malignancies. In the tumor microenvironment, FcγRIIb expression on tumor-associated macrophages (TAMs) impedes antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC), thereby limiting the efficacy of therapeutic monoclonal antibodies. This reference manual provides an exhaustive, publication-grade analysis of the *FCGR2B* gene, covering its genomic architecture, 3D protein structure, signaling pathways, pathogenic mutations, host-pathogen interactions, pharmacogenomics, and bioinformatic resources.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | FCGR2B |
| UniProt Accession | P31994 |
| Representative PDB ID | true (multiple structures available; see Section 2) |
| Chromosomal Locus | 1q23.3 (within the FCGR gene cluster) |
| Primary Molecular Function | Low-affinity inhibitory IgG Fc receptor; ITIM-mediated negative regulation of immune signaling |
| Disease & Pathology Associations | SLE, anti-GBM disease, IgA nephropathy, ITP, rheumatoid arthritis, follicular lymphoma, glioblastoma, ovarian cancer, hemophilia A inhibitors, RBC alloimmunization, ankylosing spondylitis, Alzheimer's disease |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Location and Gene Cluster Architecture

*FCGR2B* is located on the long arm of human chromosome 1 at cytogenetic band **1q23.3**, embedded within a highly complex and evolutionarily dynamic cluster of low-affinity Fc gamma receptor genes [1]. This cluster, spanning approximately 200 kb, contains, in centromeric-to-telomeric order: *FCGR2A*, *FCGR2B*, *FCGR2C*, *FCGR3A*, and *FCGR3B*. The genomic organization is characterized by extensive segmental duplications, non-allelic homologous recombination (NAHR) events, and copy number variation (CNV), which collectively contribute to inter-individual and inter-population genetic diversity [2, 3, 4]. The *FCGR2B* gene itself spans approximately 20 kb and consists of **10 exons** (Figure 1). Exon 1 encodes the 5' untranslated region (UTR) and the signal peptide; exons 2–4 encode the two extracellular immunoglobulin-like domains (EC1 and EC2); exon 5 encodes the transmembrane domain; and exons 6–10 encode the cytoplasmic tail, including the immunoreceptor tyrosine-based inhibitory motif (ITIM) [5].

```mermaid
graph TD
    A["Chromosome 1q23.3"] --> B["FCGR Gene Cluster"]
    B --> C["FCGR2A"]
    B --> D["FCGR2B"]
    B --> E["FCGR2C"]
    B --> F["FCGR3A"]
    B --> G["FCGR3B"]
    D --> H["Exon 1: 5' UTR + Signal Peptide"]
    D --> I["Exons 2-4: EC1 + EC2 Domains"]
    D --> J["Exon 5: Transmembrane Domain"]
    D --> K["Exons 6-10: Cytoplasmic Tail + ITIM"]
```

**Figure 1. Genomic organization of the FCGR gene cluster on chromosome 1q23.3.** The *FCGR2B* gene is flanked by *FCGR2A* and *FCGR2C*, with *FCGR3A* and *FCGR3B* located telomerically. The exon-intron structure of *FCGR2B* is depicted, highlighting the functional domains encoded by each exon.

### 1.2 Promoter Architecture and Transcriptional Regulation

The *FCGR2B* promoter region is a focal point of genetic variation that directly impacts transcriptional activity and disease susceptibility. Two critical single nucleotide polymorphisms (SNPs) have been characterized in the proximal promoter: **−386 G/C (rs3219018)** and **−120 A/T (rs34701572)**. These SNPs form three major promoter haplotypes: **−386G/−120A** (the common haplotype), **−386C/−120A**, and **−386C/−120T** [6]. Functional reporter assays have demonstrated that the −386C/−120T haplotype exhibits significantly reduced transcriptional activity compared to the common haplotype, leading to decreased FcγRIIb expression on B cells and monocytes [6, 7, 8, 9]. The molecular mechanism underlying this reduced activity involves altered binding of transcription factors, including members of the **GATA family** and **AP-1 (activator protein-1)** complexes, to the polymorphic promoter region [6, 7].

A third promoter polymorphism, **−343 G/C (rs3219019)**, has been independently associated with SLE susceptibility in multiple ethnic groups [8, 9]. The −343C allele creates a binding site for the transcription factor **GATA-1**, which paradoxically results in reduced promoter activity in B cells, likely due to context-dependent transcriptional interference [8]. Electrophoretic mobility shift assays (EMSAs) have confirmed differential protein-DNA complex formation between the −343G and −343C alleles [9]. The cumulative effect of these promoter SNPs is a quantitative reduction in FcγRIIb surface expression, which lowers the activation threshold of B cells and myeloid cells, thereby promoting autoantibody production and immune complex-mediated inflammation [6, 7, 8].

### 1.3 Alternative Splicing and Isoforms

Alternative splicing of *FCGR2B* generates two major membrane-bound isoforms, **FcγRIIb1** and **FcγRIIb2**, which differ in the cytoplasmic domain. FcγRIIb1, the predominant isoform on B cells, contains a 47-amino acid insertion (encoded by exon 6) that disrupts the internalization motif, rendering it incapable of mediating endocytosis but fully competent for ITIM signaling. FcγRIIb2, expressed on myeloid cells (monocytes, macrophages, neutrophils, and mast cells), lacks this insertion and possesses a functional internalization motif, enabling efficient ligand-mediated endocytosis and antigen presentation [5]. A third isoform, **FcγRIIb3**, has been described but is expressed at very low levels and lacks a functional transmembrane domain, likely representing a soluble or intracellular variant [5].

In addition to membrane-bound isoforms, a soluble form of FcγRIIb (sFcγRIIb) can be generated through proteolytic cleavage of the membrane-bound receptor or through alternative splicing that skips the transmembrane exon. sFcγRIIb has been detected in human serum and may function as a decoy receptor, competing with membrane-bound FcγRs for immune complex binding and thereby modulating immune responses [5].

### 1.4 Enhancer Elements and Long-Range Regulation

Chromatin immunoprecipitation sequencing (ChIP-seq) and Hi-C data from the ENCODE project have identified several putative enhancer elements within the *FCGR2B* locus, particularly in intronic regions and in the intergenic space between *FCGR2B* and *FCGR2C*. These enhancers are enriched for histone marks associated with active chromatin (H3K27ac, H3K4me1) in B cells and monocytes, and they physically interact with the *FCGR2B* promoter through chromatin looping. The transcription factor **PU.1**, a master regulator of myeloid and B-cell development, binds to multiple sites within these enhancers and is required for optimal *FCGR2B* expression [1]. Additionally, the **BET (bromodomain and extraterminal) family** of proteins, particularly BRD2 and BRD4, have been shown to regulate *FCGR2B* transcription in microglia, suggesting a role for epigenetic readers in controlling FcγRIIb expression in the central nervous system [1].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Boundaries

The human FcγRIIb protein (UniProt P31994) is a type I transmembrane glycoprotein of **310 amino acids** (mature form after signal peptide cleavage). The domain architecture, from N-terminus to C-terminus, is as follows:

- **Signal peptide (aa 1–42):** Cleaved during translocation to the endoplasmic reticulum.
- **Extracellular domain 1 (EC1, aa 43–130):** Immunoglobulin-like domain, membrane-distal.
- **Extracellular domain 2 (EC2, aa 131–217):** Immunoglobulin-like domain, membrane-proximal; contains the IgG Fc binding site.
- **Transmembrane domain (aa 218–240):** Hydrophobic α-helix anchoring the receptor in the plasma membrane.
- **Cytoplasmic tail (aa 241–310):** Contains the ITIM motif (aa 292–297, **AENTITYSLLKHP**), which is the effector domain for inhibitory signaling.

The two extracellular domains adopt the characteristic **immunoglobulin (Ig) fold**, consisting of a β-sandwich of two antiparallel β-sheets stabilized by a conserved disulfide bond. EC2 contains the primary binding site for the Fc portion of IgG, with critical contact residues located in the C'–E loop and the F–G loop [5].

### 2.2 Structural Basis of IgG Fc Binding

The interaction between FcγRIIb and IgG Fc is characterized by a **1:1 stoichiometry** and a low affinity (Kd ≈ 1–5 μM for monomeric IgG), which is typical of the low-affinity FcγRs. The binding interface involves the **lower hinge region** of IgG Fc (residues 234–239) and the **BC, C'–E, and F–G loops** of the EC2 domain of FcγRIIb. Key amino acid residues in FcγRIIb that contribute to Fc binding include **Leu159, His131, and Tyr157**, which form hydrophobic and electrostatic contacts with the Fc hinge [5]. The low affinity of monomeric IgG binding ensures that FcγRIIb is not constitutively occupied by serum IgG, allowing for the specific recognition of multivalent immune complexes, which crosslink the receptor and trigger signaling.

### 2.3 The ITIM Motif and Structural Basis of Inhibition

The cytoplasmic tail of FcγRIIb contains a single **ITIM** with the consensus sequence **I/V/LxYxxL/V** (residues 292–297: **AENTITYSLLKHP**). Upon receptor crosslinking by immune complexes, the ITIM tyrosine (Tyr293) is phosphorylated by Src family kinases, creating a docking site for the SH2 domain of the inositol 5'-phosphatase **SHIP1 (SH2 domain-containing inositol 5'-phosphatase 1)**. The crystal structure of the SHIP1 SH2 domain in complex with a phospho-ITIM peptide from FcγRIIb has revealed that the phosphotyrosine binds in a deep pocket, while the +3 and +5 residues (Leu296 and Leu298) make hydrophobic contacts with the SH2 domain, conferring specificity [5]. This interaction is the initiating event for the inhibitory signaling cascade (see Section 3).

### 2.4 Post-Translational Modifications and Structural Dynamics

FcγRIIb is **N-glycosylated** at two sites in the extracellular domain (Asn65 and Asn172). Glycosylation is essential for proper protein folding, cell surface expression, and IgG binding affinity. The glycan structures are heterogeneous and can modulate the receptor's interaction with IgG glycoforms, particularly those with altered fucosylation or sialylation [5]. Additionally, FcγRIIb can undergo **palmitoylation** at a cysteine residue in the transmembrane domain, which promotes its partitioning into lipid rafts and facilitates signaling [5].

### 2.5 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load FCGR2B (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P31994)

The interactive visualizer provides a fully rotatable, atomistic model of the FcγRIIb extracellular domain in complex with IgG Fc, based on X-ray crystallographic structures. Users can toggle between cartoon, surface, and electrostatic potential representations; highlight the ITIM motif in the cytoplasmic domain; and measure distances between key contact residues. This tool is indispensable for researchers investigating the structural basis of FcγRIIb function and for structure-based drug design efforts.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Inhibitory Signaling Cascade in B Cells

FcγRIIb is the only Fcγ receptor expressed on B cells, where it functions as a critical negative regulator of BCR signaling. Co-crosslinking of the BCR and FcγRIIb by immune complexes containing IgG triggers the following cascade:

1. **ITIM phosphorylation:** Src family kinases (Lyn, Fyn) phosphorylate Tyr293 within the ITIM.
2. **SHIP1 recruitment:** Phosphorylated ITIM recruits SHIP1 via its SH2 domain.
3. **PIP3 hydrolysis:** SHIP1 dephosphorylates phosphatidylinositol 3,4,5-trisphosphate (PIP3) to phosphatidylinositol 3,4-bisphosphate (PI(3,4)P2), thereby reducing the membrane concentration of PIP3.
4. **Inhibition of BCR signaling:** The reduction in PIP3 prevents the membrane recruitment and activation of **BTK (Bruton's tyrosine kinase)** and **PLCγ2 (phospholipase C gamma 2)**, which are essential for calcium mobilization and downstream signaling via NF-κB, NFAT, and MAPK pathways.
5. **Apoptosis and tolerance:** In germinal center B cells, FcγRIIb signaling can also promote apoptosis, contributing to the elimination of autoreactive B cells and the maintenance of peripheral tolerance [2, 3].

The critical role of FcγRIIb in B-cell tolerance is underscored by the observation that *Fcgr2b*-deficient mice develop spontaneous SLE-like autoimmunity, characterized by hypergammaglobulinemia, anti-dsDNA antibodies, and immune complex glomerulonephritis [4, 5, 6, 7]. Conversely, overexpression of FcγRIIb on B cells protects against autoimmunity in mouse models [2].

### 3.2 FcγRIIb Signaling in Myeloid Cells

On monocytes, macrophages, and dendritic cells, FcγRIIb opposes the activating signals mediated by ITAM-bearing FcγRs (FcγRI, FcγRIIa, FcγRIIIa). Co-engagement of FcγRIIb with activating FcγRs by immune complexes results in:

- **Inhibition of phagocytosis:** SHIP1-mediated PIP3 depletion impairs actin polymerization and phagosome formation, reducing the uptake of opsonized pathogens and tumor cells [8].
- **Suppression of pro-inflammatory cytokine release:** FcγRIIb signaling inhibits the production of TNF-α, IL-6, and IL-12 while promoting the secretion of anti-inflammatory cytokines such as IL-10 [8].
- **Inhibition of antigen presentation:** FcγRIIb crosslinking reduces MHC class II expression and antigen presentation to T cells, dampening adaptive immune responses [8].

In the tumor microenvironment, hypoxia upregulates FcγRIIb expression on TAMs via **HIF (hypoxia-inducible factor)** signaling, rendering these cells refractory to antibody-mediated phagocytosis and thereby limiting the efficacy of therapeutic monoclonal antibodies such as rituximab and trastuzumab [8]. This mechanism represents a major barrier to cancer immunotherapy and has motivated the development of FcγRIIb-blocking agents (see Section 6).

### 3.3 FcγRIIb in Dendritic Cells and T Cell Regulation

FcγRIIb on dendritic cells (DCs) modulates the balance between immunity and tolerance. In the absence of FcγRIIb, DCs exhibit enhanced antigen presentation and increased production of pro-inflammatory cytokines, leading to stronger T helper 1 (Th1) and Th17 responses [2]. FcγRIIb also plays a role in the induction of regulatory T cells (Tregs) by promoting the generation of tolerogenic DCs [2]. In a collagen-induced arthritis (CIA) model, the combination of *Ncf1* and *Fcgr2b* mutations additively disrupted T cell tolerance, highlighting the synergistic interaction between oxidative burst and FcγRIIb signaling in maintaining immune homeostasis [2].

### 3.4 FcγRIIb in Non-Hematopoietic Cells

FcγRIIb is expressed on certain non-hematopoietic cells, including **hepatic sinusoidal endothelial cells**, **mesangial cells of the kidney**, and **neurons**. In the brain, the FcγRIIb2 isoform mediates the uptake of amyloid-β oligomers (AβO) into neurons, contributing to the intracellular accumulation of Aβ and neurodegeneration in Alzheimer's disease (AD) [9]. The adaptor protein **TOM1 (target of Myb1)** interacts with the FcγRIIb2 cytoplasmic tail and regulates the trafficking of internalized AβO, suggesting a potential therapeutic target for AD [9].

### 3.5 Protein-Protein Interaction Networks

The FcγRIIb interactome, as curated in BioGRID and STRING, includes:

- **SHIP1 (INPP5D):** Primary effector of ITIM signaling.
- **SHIP2 (INPPL1):** Alternative SH2-containing inositol phosphatase.
- **DOK1 (Downstream of tyrosine kinase 1):** Adaptor protein that recruits SHIP1 to the plasma membrane.
- **Grb2 (Growth factor receptor-bound protein 2):** Involved in MAPK pathway modulation.
- **Lyn:** Src family kinase responsible for ITIM phosphorylation.
- **SHP-1 (PTPN6):** Protein tyrosine phosphatase that can also bind the ITIM under certain conditions.
- **TOM1:** Regulates endocytic trafficking in neurons [9].
- **BCAP (PIK3AP1):** Links FcγRIIb to PI3K signaling in B cells.

### 3.6 Regulatory Feedback Loops

FcγRIIb expression is subject to complex feedback regulation. **Interferon-γ (IFN-γ)** upregulates FcγRIIb on myeloid cells, while **IL-4** and **IL-10** have variable effects depending on cell type. In SLE, the **cGAS-STING-TBK1 axis** is activated in CD4+ T cells from *Fcgr2b*-deficient mice, leading to enhanced T cell activation and autoimmunity [1]. This suggests a feed-forward loop whereby FcγRIIb deficiency promotes type I IFN signaling, which in turn exacerbates autoimmune pathology [1, 4]. Additionally, the **Myc-miR-17-92 axis** has been shown to downregulate FcγRIIb expression in B-cell lymphomas by targeting the 3' UTR of *FCGR2B* mRNA, thereby amplifying BCR signaling and promoting lymphomagenesis [2].

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Non-Synonymous Coding Variants

The most extensively studied non-synonymous SNP in *FCGR2B* is **rs1050501 (c.695T>C, p.Ile232Thr)**, located in the transmembrane domain. The 232Thr allele is associated with reduced FcγRIIb surface expression and impaired inhibitory function, likely due to altered membrane trafficking or lipid raft partitioning [3, 4, 5]. This variant has been associated with:

- **Systemic lupus erythematosus (SLE):** The 232Thr allele is enriched in SLE patients across multiple ethnic groups, including Japanese, Chinese, and Thai populations [4, 5, 6, 7].
- **Hemophilia A inhibitor development:** The 232I/T polymorphism is associated with the development of neutralizing antibodies against factor VIII in Chinese hemophilia A patients [3].
- **Immune thrombocytopenia (ITP):** The 232Thr allele may influence susceptibility to childhood ITP [8].

A second coding variant, **rs1050502 (c.695T>C, p.Ile232Thr)** is a misannotation; the correct rsID for the Ile232Thr variant is rs1050501. Other rare coding variants have been identified through large-scale sequencing efforts, but their functional significance remains largely uncharacterized.

### 4.2 Promoter Polymorphisms and Haplotype Structure

As described in Section 1.2, the promoter SNPs **−386 G/C (rs3219018)** and **−120 A/T (rs34701572)** define three major haplotypes with differential transcriptional activity [6]. The low-expressing **−386C/−120T** haplotype is associated with SLE susceptibility [6]. The **−343 G/C (rs3219019)** SNP is also associated with SLE and reduced promoter activity [8, 9]. These promoter variants are in linkage disequilibrium with coding variants, creating extended risk haplotypes that collectively reduce FcγRIIb expression and function [6].

### 4.3 Copy Number Variation and Structural Rearrangements

The FCGR locus is subject to extensive CNV, particularly involving *FCGR3A*, *FCGR3B*, and *FCGR2C*, but *FCGR2B* is generally refractory to CNV due to its unique genomic context [2, 3]. However, non-allelic homologous recombination (NAHR) events can generate chimeric *FCGR2B/FCGR2C* genes with aberrant expression patterns [4]. These chimeras can produce FcγRIIb proteins with altered signaling properties, potentially contributing to autoimmune phenotypes [4].

### 4.4 Chromosomal Translocations in Lymphoma

*FCGR2B* is a target for chromosomal translocations in malignant lymphoma. The t(1;2)(q23;p13) translocation, which juxtaposes *FCGR2B* with the *BCL11A* locus, has been identified in follicular lymphoma and results in deregulated *FCGR2B* expression [1, 9]. Similarly, a complex karyotype involving t(1;2)/FCGR2B has been reported in acute lymphoblastic leukemia [2]. These translocations likely contribute to lymphomagenesis by disrupting the normal balance of activating and inhibitory FcγR signaling, thereby promoting B-cell survival and proliferation [1, 9].

### 4.5 Disease Associations and Clinical Differentials

| **Disease** | **Variant/Mechanism** | **Clinical Consequence** | **Reference** |
|---|---|---|---|
| Systemic Lupus Erythematosus | Promoter haplotypes (−386C/−120T, −343C); Ile232Thr | Reduced FcγRIIb expression; loss of B-cell tolerance; autoantibody production | [4, 5, 6, 7, 8, 9] |
| Anti-GBM Disease | Promoter SNPs; CNV of FCGR3A | Altered immune complex clearance; increased susceptibility | [3, 4, 5] |
| IgA Nephropathy | FCGR2B and FCRLB polymorphisms | Impaired clearance of IgA-containing immune complexes | [6] |
| Immune Thrombocytopenia | Ile232Thr | Altered platelet clearance | [8] |
| Hemophilia A Inhibitors | Ile232Thr | Increased risk of FVIII inhibitor development | [3] |
| Rheumatoid Arthritis | FCGR3A/FCGR3B haplotypes; epistasis with HLA-DRB1 | Modulates disease susceptibility and severity | [7, 8] |
| Ankylosing Spondylitis | rs10917661 | Increased susceptibility in Han Chinese | [1, 9] |
| Follicular Lymphoma | t(1;2)(q23;p13) translocation | Deregulated FCGR2B expression | [1, 9] |
| Glioblastoma | Transcriptomic upregulation | Poor prognosis; immune evasion | [2, 3, 4, 5, 6, 7] |
| High-Grade Serous Ovarian Cancer | FCGR2B+ TAMs | Ferroptosis-immunosuppression link; poor prognosis | [8] |
| Colorectal Cancer | Phagocytosis-related gene signature | Prognostic biomarker | [9] |
| Sickle Cell Disease | B2.4 haplotype | Increased RBC alloimmunization risk | [1, 2] |
| Alzheimer's Disease | FcγRIIb2-mediated Aβ uptake | Neuronal Aβ accumulation | [9] |
| Pulmonary Sarcoidosis/TB | FCGR polymorphisms | Differential monocyte phagocytic activity | [3] |

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 FcγRIIb and Viral Immune Evasion

FcγRIIb plays a dual role in viral infections. On one hand, it can limit antibody-dependent enhancement (ADE) of viral infection by competing with activating FcγRs for immune complex binding. On the other hand, some viruses exploit FcγRIIb to suppress antiviral immune responses. For example, in the context of **Zika virus (ZIKV)** infection, FcγRI (CD64) has been identified as the key determinant of antibody-mediated infection of placental macrophages, but FcγRIIb may modulate the balance between enhancement and neutralization [4]. The expression level of FcγRIIb on macrophages could influence the outcome of ADE, with higher FcγRIIb expression potentially reducing viral uptake via activating receptors [4].

### 5.2 Bacterial and Parasitic Infections

FcγRIIb polymorphisms have been associated with susceptibility to **Plasmodium falciparum** malaria. A non-coding cis-regulatory variant within the 1q23 gene cluster, which includes *FCGR2B*, is associated with P. falciparum infection in children from Burkina Faso [5]. This variant likely alters FcγRIIb expression on monocytes and macrophages, affecting the clearance of opsonized parasites and the balance between protective and pathogenic immune responses [5].

In **mycobacterial infections**, including tuberculosis, FcγRIIb expression on monocytes is altered, and FCGR polymorphisms may influence disease susceptibility and clinical outcome [3, 6]. The phagocytic activity of monocytes is reduced in sarcoidosis and tuberculosis, and this reduction is associated with changes in FcγR expression patterns [3].

### 5.3 Parasitic Infections: Theileria annulata

*Theileria annulata*, an apicomplexan parasite that transforms bovine leukocytes, induces extensive genomic alterations in host cells, including changes in *FCGR2B* expression [7]. The transformed leukocytes exhibit cancer-like phenotypes, and the deregulation of FcγRIIb may contribute to the survival and proliferation of infected cells by modulating immune signaling [7].

### 5.4 Immune Evasion in Cancer

In the tumor microenvironment, FcγRIIb on TAMs serves as a checkpoint that suppresses antibody-mediated anti-tumor immunity. Hypoxia upregulates FcγRIIb via HIF signaling, and this upregulation is associated with resistance to therapeutic monoclonal antibodies [8]. Additionally, FcγRIIb expression on tumor cells themselves has been reported in certain malignancies, where it may sequester IgG and prevent ADCC/ADCP [5]. These mechanisms represent a form of "host-pathogen" interaction in which the tumor exploits an inhibitory immune receptor to evade destruction.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 FcγRIIb as a Target for Cancer Immunotherapy

The inhibitory function of FcγRIIb on TAMs and B cells makes it an attractive target for cancer immunotherapy. Blocking FcγRIIb with monoclonal antibodies or small molecules can enhance the efficacy of therapeutic antibodies by:

- **Restoring ADCP:** Anti-FcγRIIb antibodies (e.g., the investigational agent **BI-1206**) prevent FcγRIIb-mediated inhibition of phagocytosis, thereby enhancing the clearance of opsonized tumor cells [8].
- **Enhancing B-cell depletion:** In B-cell malignancies, FcγRIIb on malignant B cells can compete with activating FcγRs for rituximab binding, reducing ADCC. Blocking FcγRIIb can increase rituximab-mediated killing [8].

**BI-1206**, a humanized monoclonal antibody targeting FcγRIIb, is currently in Phase 1/2 clinical trials for relapsed/refractory B-cell lymphomas in combination with rituximab. Preclinical studies have demonstrated that BI-1206 enhances rituximab-induced ADCP and ADCC and overcomes resistance to rituximab in xenograft models [8].

### 6.2 Pharmacogenomics of FCGR2B Variants

*FCGR2B* polymorphisms influence the response to several therapeutic agents:

- **Rituximab:** The Ile232Thr variant may affect rituximab-mediated B-cell depletion and clinical response in autoimmune diseases and lymphoma [8].
- **Cyclophosphamide (CYC):** Polymorphisms in the *FCGR2B-FCRLA* locus are associated with response to intravenous CYC treatment for lupus nephritis [1, 9]. Patients with certain risk genotypes may require alternative immunosuppressive regimens.
- **Intravenous immunoglobulin (IVIG):** FcγRIIb is a key mediator of IVIG's anti-inflammatory effects. Upregulation of FcγRIIb on macrophages by IVIG is thought to contribute to its therapeutic efficacy in ITP and other autoimmune diseases [8].

### 6.3 Small-Molecule Inhibitors and Gene Therapy

While no small-molecule inhibitors of FcγRIIb have been approved, the ITIM-SHIP1 interaction represents a potential druggable target. Peptide-based inhibitors that block SHIP1 binding to the phospho-ITIM have been developed in preclinical models and could be used to modulate FcγRIIb signaling [5]. Additionally, gene therapy approaches aimed at overexpressing FcγRIIb on B cells are being explored as a strategy to restore immune tolerance in autoimmune diseases [2].

### 6.4 FcγRIIb in Radiotherapy and Chemotherapy

Transcriptomic analyses have identified *FCGR2B* as a component of gene signatures that predict response to radiotherapy in prostate cancer and glioblastoma [2, 4]. High *FCGR2B* expression is associated with an immunosuppressive tumor microenvironment and poor response to radiation, suggesting that FcγRIIb blockade could be combined with radiotherapy to enhance anti-tumor immunity [4].

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **Description** |
|---|---|---|
| NCBI Gene | 2213 | Gene ID for human FCGR2B |
| Ensembl | ENSG00000069712 | Ensembl gene ID |
| UniProt | P31994 | Protein sequence and functional annotation |
| RCSB PDB | 2FCB, 3WJL, 4X4M (and others) | X-ray structures of FcγRIIb extracellular domain (alone or in complex with IgG Fc) |
| HGNC | 3618 | Official gene symbol and nomenclature |
| OMIM | 604590 | Mendelian inheritance and disease associations |
| ClinVar | Various | Pathogenic and benign variants |
| dbSNP | rs1050501, rs3219018, rs34701572, rs3219019 | Key SNPs |
| Gene Ontology (GO) | GO:0005886 (plasma membrane), GO:0019864 (IgG binding), GO:0007166 (cell surface receptor signaling) | Molecular function, cellular component, biological process |
| STRING | P31994 | Protein-protein interaction network |
| BioGRID | 112233 | Physical and genetic interactions |
| TCGA | FCGR2B | Expression data across cancer types |
| GTEx | FCGR2B | Tissue-specific expression and eQTL data |

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)

## References

[1] Xiao, M. (2005). Gene mutation and its effects of IgG hypergammaglobulinemia susceptibility gene-Fcgr2b gene in model of systemic lupus erythematosus. *Scientific Publication*. https://www.semanticscholar.org/paper/41221f70fb2da03b52d19d773920257eb2d2fe9f

[2] FCGR2B Gene. (2020). *Definitions*. https://www.semanticscholar.org/paper/848d5e137cbecdd385cc202d533f38fd78ad48a7

[3] Xiu, Y., Nakamura, K., Abe, M., Li, N., Wen, X., Jiang, Y., Zhang, D., Tsurui, H., Matsuoka, S., Hamano, Y., Fujii, H., Ono, M., Takai, T., Shimokawa, T., Ra, C., Shirai, T., & Hirose, S. (2002). Transcriptional Regulation of Fcgr2b Gene by Polymorphic Promoter Region and Its Contribution to Humoral Immune Responses. *Journal of Immunology*. https://www.semanticscholar.org/paper/ddb4a1432f50de0184736fc0c187d86d69154a13

[4] Blank, M., Stefanescu, R. N., Masuda, E., Martí, F., King, P., Redecha, P., Wurzburger, R. J., Peterson, M. G. E., Tanaka, S., & Pricop, L. (2005). Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus. *Human Genetics*. https://www.semanticscholar.org/paper/25ce6112a19096e069d5b0a0534d8be524685361

[5] Zhou, X., Lv, J., Yu, L., Cui, Z., Zhao, J., Yang, R., Han, J., Hou, P., Zhao, M., & Zhang, H. (2010). FCGR2B gene polymorphism rather than FCGR2A, FCGR3A and FCGR3B is associated with anti-GBM disease in Chinese. *Nephrology, Dialysis and Transplantation*. https://www.semanticscholar.org/paper/73b30076f1f534b27d5e4f3869cfa1156743c945

[6] Olferiev, M., Masuda, E., Blank, M., & Pricop, L. (2007). Transcriptional regulation of the human FCGR2B gene mediated by promoter polymorphisms associated with Systemic Lupus Erythematosus. *Journal of Immunology*. https://www.semanticscholar.org/paper/796a9c11f1e3c3dfc0796c735ec82f79d6216e7b

[7] Zhou, J., Zeng, T., Liu, Y., Ye, M., Li, M., Zhang, Z., & Meng, Y. (2026). FCGR2B+ Macrophages as a Critical Node Linking Ferroptosis and Immunosuppression: A Multiomics Framework for Prognosis and Therapy in High-Grade Serous Ovarian Cancer. *Human Mutation*. https://www.semanticscholar.org/paper/3b93f9a485f48e5fe12457986751695e6ea1ba89

[8] Kasap, B. K., Toraman, B., Kurt, B., Ermis, H., & Arıca, D. (2026). Genetic and immunological determinants of Pemphigus vulgaris: integrative analysis of HLA-DRB1 and FCGR2B variants. *Immunogenetics*. https://www.semanticscholar.org/paper/d3824add1c5f805a603678e5ff8ae22b4e79ff42

[9] Sun, Z.,